Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study.

"Declarations Ethics approval and consent to participateThe study was approved by the local medical ethical committee. All human subjects provided online informed consent for their data to be used for research purposes. Consent for publicationNot applicable. Competing interestsLNCV has been an invited speaker by the Schwabe Group; fees were paid to her institution. JS wrote a book for a layman’s audience about the personal impact of dominantly inherited Alzheimer’s disease, for which she received grants or contracts from Aegon Nederland and Alzheimer Nederland and royalties from Uitgeverij Prometheus. JS is a member of the advisory board for the National Dementia Strategy of the Dutch Ministry of Health, Welfare and Sport. SAMS provided consultancy services to Prothena Biosciences, Aribio, and Biogen, and she is part of the Scientific Advisory Board of Cogstate. Alle funds are paid to the institution. PS has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell, and Green Valley. Within his university affiliation, PS is a global PI of the phase 1b study of AC Immune, phase 2b study with FUJI-film/Toyama, and phase 2 study of UCB. He is a past chair of the EU steering committee of the phase 2b programme of Vivoryon and the phase 2b study of Novartis Cardiology and presently co-chair of the phase 3 study with NOVO-Nordisk. WF has performed contract research for Biogen MA Inc. and Boehringer Ingelheim. All funding is paid to her institution. WF has been an invited speaker at Biogen MAInc, Danone, Eisai, Novonordisk, Web MD Neurology (Medscape), Springer Healthcare, and European Brain Council. WF is a consultant to Oxford Health Policy Forum CIC, Roche, Eisai, and Biogen MA Inc. WF participated on advisory boards of Biogen MAI Inc., Roche, and EliLilly. All funding is paid to her institution. WF is a member of the steering committee of PAVE and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. LW, LAM, SC, SL, ACH, and MZ report no conflicts of interest. Competing interests LNCV has been an invited speaker by the Schwabe Group; fees were paid to her institution. JS wrote a book for a layman’s audience about the personal impact of dominantly inherited Alzheimer’s disease, for which she received grants or contracts from Aegon Nederland and Alzheimer Nederland and royalties from Uitgeverij Prometheus. JS is a member of the advisory board for the National Dementia Strategy of the Dutch Ministry of Health, Welfare and Sport. SAMS provided consultancy services to Prothena Biosciences, Aribio, and Biogen, and she is part of the Scientific Advisory Board of Cogstate. Alle funds are paid to the institution. PS has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell, and Green Valley. Within his university affiliation, PS is a global PI of the phase 1b study of AC Immune, phase 2b study with FUJI-film/Toyama, and phase 2 study of UCB. He is a past chair of the EU steering committee of the phase 2b programme of Vivoryon and the phase 2b study of Novartis Cardiology and presently co-chair of the phase 3 study with NOVO-Nordisk. WF has performed contract research for Biogen MA Inc. and Boehringer Ingelheim. All funding is paid to her institution. WF has been an invited speaker at Biogen MAInc, Danone, Eisai, Novonordisk, Web MD Neurology (Medscape), Springer Healthcare, and European Brain Council. WF is a consultant to Oxford Health Policy Forum CIC, Roche, Eisai, and Biogen MA Inc. WF participated on advisory boards of Biogen MAI Inc., Roche, and EliLilly. All funding is paid to her institution. WF is a member of the steering committee of PAVE and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. LW, LAM, SC, SL, ACH, and MZ report no conflicts of interest."

"Funding WF and MZ are recipients of a NWO project on Maintaining Optimal Cognitive function In Ageing (MOCIA # 17611). PS is a recipient of Joint Program of Neurodegenerative Disorders – (EU-FINGERS: multimodal precision prevention toolbox for dementia in Alzheimer’s disease) grant (through the following funding organisations under the aegis of JPND—www.jpnd.eu: Finland, Academy of Finland; Germany, Federal Ministry of Education and Research; Spain, National Institute of Health Carlos III; Luxemburg, National Research Fund; Hungary, National Research, Development and Innovation Office; The Netherlands, Netherlands Organisation for Health Research and Development (ZonMW-Memorabel #733051102); Sweden, Swedish Research Council). LNCV, PS, SL, MZ, and WF are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). PS is a full-time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. SL is a recipient of ZonMW funding (#733050512). SAMS is a recipient of Health~Holland, Topsector Life Sciences & Health (PPP-allowance LSHM19051, LSHM20084; LSHM22026-SGF), and ZonMW (#10510032120003 and #7330502051 and #73305095008)."